An Open-Label, Multicenter, Pharmacokinetic Study of Trabectedin in Subjects With Advanced Malignancies and Hepatic Dysfunction

Trial Profile

An Open-Label, Multicenter, Pharmacokinetic Study of Trabectedin in Subjects With Advanced Malignancies and Hepatic Dysfunction

Completed
Phase of Trial: Phase I

Latest Information Update: 07 Jun 2016

At a glance

  • Drugs Trabectedin (Primary) ; Dexamethasone
  • Indications Solid tumours
  • Focus Pharmacokinetics
  • Sponsors Janssen Research & Development
  • Most Recent Events

    • 07 Jun 2016 Results related to liver toxicity of Trabectedin from OVC1004 and SAR3007 studies presented at the 52nd Annual Meeting of the American Society of Clinical Oncology.
    • 19 May 2016 According to PharmaMar media release, results will be presented at the 52nd Congress of the American Society of Clinical Oncology (ASCO).
    • 31 Jul 2015 Status changed from recruiting to completed as per ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top